Tags

Type your tag names separated by a space and hit enter

Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
Arch Med Res. 2020 08; 51(6):595-597.AM

Abstract

Presently, we need more therapeutic molecules for this COVID-19 outbreak. The severity and mortality of the disease is associated with a high level of release of cytokine in the patients which is known as CRS (cytokine release syndrome) or cytokine storm syndrome. IL-6 is a type of pro-inflammatory cytokine which release in the severe COVID-19 patients. This cytokine initiates CRS the JAK-STAT or MAPK/NF-κB-IL-6 pathway. Tocilizumab, a humanized monoclonal antibody, is designed to bind both mIL-6R (membrane bound receptor for IL-6) and sIL-6R (soluble receptor for IL-6) and inhibit the JAK-STAT or MAPK/NF-κB-IL-6 signaling pathway. It finally stops the cytokine storm syndrome. However, we need to understand that how tocilizumab is bound with mIL-6R or sIL-6R. Similarly, we also need to understand more about the real molecular mechanism of activity of tocilizumab.

Authors+Show Affiliations

Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Kolkata, West Bengal, India.Institute for Skeletal Aging and Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon-si, Gangwon-do, South Korea.Department of Zoology, Fakir Mohan University, Balasore, Odisha, India.Neuropsychopharmacology and Toxicology Program, College of Pharmacy, Kangwon National University, Gangwon-do, South Korea.Institute for Skeletal Aging and Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon-si, Gangwon-do, South Korea.Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Kolkata, West Bengal, India. Electronic address: 123sslee@gmail.com.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32482373

Citation

Saha, Abinit, et al. "Tocilizumab: a Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19." Archives of Medical Research, vol. 51, no. 6, 2020, pp. 595-597.
Saha A, Sharma AR, Bhattacharya M, et al. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19. Arch Med Res. 2020;51(6):595-597.
Saha, A., Sharma, A. R., Bhattacharya, M., Sharma, G., Lee, S. S., & Chakraborty, C. (2020). Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19. Archives of Medical Research, 51(6), 595-597. https://doi.org/10.1016/j.arcmed.2020.05.009
Saha A, et al. Tocilizumab: a Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19. Arch Med Res. 2020;51(6):595-597. PubMed PMID: 32482373.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19. AU - Saha,Abinit, AU - Sharma,Ashish Ranjan, AU - Bhattacharya,Manojit, AU - Sharma,Garima, AU - Lee,Sang-Soo, AU - Chakraborty,Chiranjib, Y1 - 2020/05/21/ PY - 2020/05/14/received PY - 2020/05/15/accepted PY - 2020/6/3/pubmed PY - 2020/9/29/medline PY - 2020/6/3/entrez KW - COVID-19 KW - Cytokine storm syndrome KW - Therapeutic option KW - Tocilizumab SP - 595 EP - 597 JF - Archives of medical research JO - Arch Med Res VL - 51 IS - 6 N2 - Presently, we need more therapeutic molecules for this COVID-19 outbreak. The severity and mortality of the disease is associated with a high level of release of cytokine in the patients which is known as CRS (cytokine release syndrome) or cytokine storm syndrome. IL-6 is a type of pro-inflammatory cytokine which release in the severe COVID-19 patients. This cytokine initiates CRS the JAK-STAT or MAPK/NF-κB-IL-6 pathway. Tocilizumab, a humanized monoclonal antibody, is designed to bind both mIL-6R (membrane bound receptor for IL-6) and sIL-6R (soluble receptor for IL-6) and inhibit the JAK-STAT or MAPK/NF-κB-IL-6 signaling pathway. It finally stops the cytokine storm syndrome. However, we need to understand that how tocilizumab is bound with mIL-6R or sIL-6R. Similarly, we also need to understand more about the real molecular mechanism of activity of tocilizumab. SN - 1873-5487 UR - https://www.unboundmedicine.com/medline/citation/32482373/Tocilizumab:_A_Therapeutic_Option_for_the_Treatment_of_Cytokine_Storm_Syndrome_in_COVID_19_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0188-4409(20)30782-7 DB - PRIME DP - Unbound Medicine ER -